Bacterial spectrum and antimicrobial resistance pattern in cancer patients with febrile neutropenia. 2023

Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.

BACKGROUND Bloodstream infections are serious complications in neutropenic cancer patients. There has been a universal pickup in multidrug resistant (MDR) strains. For individuals who are at high risk for infections caused by MDR bacteria, a novel de-escalation strategy has been developed. Determine the bacterial spectrum and antibiotic resistance pattern in febrile neutropenic cancer patients was the goal of this investigation. METHODS From 2019 to 2020, 60 cancer patients with febrile neutropenia who were sent to Isfahan's Omid Hospital were included in this retrospective analysis. Experiments were done on the antimicrobial susceptibility of isolated bacterial infections. RESULTS The patients' average age was 43.35±15.59 years. Ninety-one percent (55/61) of the 60 patients had hematologic malignancies, and 8.3 percent (5/61) had solid tumors. The majority of the germs were gram-negative bacteria (66.7 percent). E. coli was the pathogen that was isolated the most frequently (26.7%), followed by Klebsiella (16.7 percent). In addition, the most prevalent identified Gram-positive bacteria was Staphylococcus epidermidis (21.7 percent). Third-generation cephalosporin (ESBL-E) resistance was present in 50% of E. coli, along with 50% resistance to cotrimoxazole, ciprofloxacin, and piperacillin, 31% resistance to amikacin, and 20% resistance to meropenem (CRE). They had an 80% sensitivity to amikacin and a 70% sensitivity to ciprofloxacin. Ten percent of our patients had antibiotic resistance in the antibiogram (XDR). CONCLUSIONS In summary, most bacterial infections were resistant to different medications. The emergence and spread of Gram-negative bacteria that are resistant to antibiotics can be stopped by prudent antibiotic use.

UI MeSH Term Description Entries

Related Publications

Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
May 2019, Asian Pacific journal of cancer prevention : APJCP,
Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
April 2013, Scandinavian journal of infectious diseases,
Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
January 2004, Journal of Ayub Medical College, Abbottabad : JAMC,
Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
June 2012, Indian journal of microbiology,
Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
June 2011, BMC infectious diseases,
Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
November 1994, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
May 2012, Current opinion in pulmonary medicine,
Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
September 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
March 2018, Clinical case reports,
Ali Darakhshandeh, and Elham Fathi, and Ali Haji Gholami, and Farzaneh Ashrafi, and Valiollah Mehrzad, and Elahe Nasri
July 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!